¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ Á¤±âÇмú´ëȸ : 2022-08-27

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ Á¤±âÇмú´ëȸ : 2022-08-27
±³À°ÀÏÀÚ : 2022-08-27
±³À°Àå¼Ò : À»ÁöÀη°³¹ß¿ø  
±³À°ÁÖÁ¦ : 2022³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ Á¤±âÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѹÙÀÌ·¯½ºÇÐȸ
´ã´çÀÚ : ÃÖ¼¼ÀÎ
¿¬¶ôó : 070-8886-3062  
À̸ÞÀÏ : virology@ksov.org      
±³À°Á¾·ù : ÀÇ»çÇйýÀÇÇп¹¹æÀÇÇÐÇغÎÇлý¸®ÇлýÈ­ÇкÐÀÚ»ý¹°Çй̻ý¹°Çбâ»ýÃæÇоฮÇР     
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : °­¿øµµ
±³À°½Ã°£ : 5 ½Ã°£ 5ºÐ  
¼¼ºÎ¼ö°­·á : 200,000¿ø      
ºñ°í ÆòÀÇ¿ø: ÀÏ¹Ý 20¸¸¿ø, Çлý 8¸¸¿ø Á¤È¸¿ø: ÀÏ¹Ý 15¸¸¿ø, Çлý 8¸¸¿ø ºñȸ¿ø: ÀÏ¹Ý 15¸¸¿ø, Çлý 8¸¸¿ø ÇöÀåµî·Ï: ÀÏ¹Ý 20¸¸¿ø, Çлý 10¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ09:30~09:50 Modeling how peginterferon alfa improves clearance rates of cccDNA in hepatitis B virus infected patients  ±è±¤¼ö(ºÎ°æ´ëÇб³ °úÇнýºÅ۽ùķ¹À̼ÇÇаú) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ09:50~10:10 Antiviral activity of activated cdc42-associated kinase 1 against hepatitis B virus  ¹Ú¿ë±¤(±¹¸³º¸°Ç¿ø ¸¸¼º¹ÙÀÌ·¯½º¿¬±¸°ú) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ10:10~10:30 Role of p62/SQSTM1 in ZIKV Pathogenesis  ±è¼ºÁØ(Çѱ¹È­Çבּ¸¿ø) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ10:30~10:45 SARS-CoV-2 productively infects human hepatocytes and induces cell death  °íõ±Ô(Çѱ¹È­Çבּ¸¿ø) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ10:45~11:00 Host sensing of RNA viruses and the viral evasion strategies: From fundamental mechanism study to the development of the screening tool  À¯Áö½Â(±âÃÊ°úÇבּ¸¿ø Çѱ¹¹ÙÀÌ·¯½º±âÃÊ¿¬±¸¼Ò) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ11:00~11:15 CaMKII Inhibits HBV Replication via AMPK/AKT/mTOR Signaling pathways  ±èÁÖ¹Ì(¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ11:15~11:30 The regulatory T cell population is not normalized following successfultreatment of chronic hepatitis C with direct-acting antivirals  ±è¼Ò¿µ(KAIST) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ13:05~13:30 Viral G-quadruplex as a promising target to control SARS-CoV-2 infection  ¼Û¹®Á¤(°í·Á´ëÇб³ »ý¸í°úÇдëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ13:30~13:55 Preparedness against Viral Disease X with active surveillance from wild life animals and nanobiotechnology for diagnosis, antiviral, and vaccine  ¼Û´ë¼·(¼­¿ï´ëÇб³ ¼öÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ13:55~14:20 Influenza and SARS-CoV-2 co-infection alters viral tropism in Syrian hamsters  À±¼±¿ì(Çѱ¹»ý¸í°øÇבּ¸¿ø) 
Åä·Ð 08-27 ´ë°­ÀǽǠ14:20~14:40 ÁúÀÇÀÀ´ä  () 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ14:40~14:52 SARS-CoV-2 omicron mainly utilizes cathepsin for infectivity and fusogenicity  ÀåÀǼø(°í·Á´ëÇб³ »ý¸íÁ¤º¸Çаú) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ14:52~15:04 Definition and correlation analysis of bimodal distribution of sequencing data of transcriptome and chromatin accessibility  ±è±¤ÈÆ(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ15:04~15:16 Single Cell Transcriptomic Analysis of Human Lung Organoids to model SARS-CoV-2 Infection  À̼¼À±(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ15:16~15:28 Aging dependent Immunopathology of the COVID-19 : The potent guardians, Innate lymphoid cells  Àӹοµ(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ15:28~15:40 Development of humanized ACE2-expressing mouse model for COVID-19  ¹Ú¿îÀÌ(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ15:40~15:52 Mutation patterns of SARS-CoV-2 through serial passage in human cell lines  ³ëÁö¿µ(ÃæºÏ´ëÇб³ »ý¸í½Ã½ºÅÛÇаú) 
Åä·Ð 08-27 ´ë°­ÀǽǠ15:52~16:10 ÁúÀÇÀÀ´ä  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ Á¤±âÇмú´ëȸ : 2022-08-27""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022³âµµ ´ëÇѽŰæ¿Ü°úÇÐȸ ´ë±¸¡¤°æºÏÁöȸ Á¦3Â÷ ¿¬¼ö±³À° : 2022-08-27
´ÙÀ½±Û 2022 ´ëÇÑ°ñ´ë»çÇÐȸ °ñ¼øȯ ½ÉÆ÷Áö¿ò (The 21st International Symposium of Association Research Circulation Osseous)(2ÀÏÂ÷) : 2022-08-27
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21120 ¼­¿ï 24³âµµ ´ëÇѱâ´ÉÀÇÇÐȸ Çϰ迬¼ö°­Á : 2024-07-14 0 25 2024-06-19
21119 ¼­¿ï ´ëÇÑÇ÷°üÇÐȸ KOVAS 2024 Summer Conference (2ÀÏÂ÷) : 2024-07-13 0 14 2024-06-19
21118 ÀüºÏ 2024³â ´ëÇÑ»ý¹°Ä¡·áÁ¤½ÅÀÇÇÐȸ Çϰ迬¼ö±³À° : 2024-07-13 0 13 2024-06-19
21117 ¼­¿ï ´ëÇÑÁ·ºÎÁ·°üÀýÇÐȸ - Á¦1ȸ ´ç´¢¹ß ½ÉÆ÷Áö¾ö : 2024-07-13 0 9 2024-06-19
21116 ¼­¿ï õ½Ä¿¬±¸È¸ Workshop 2024 : 2024-07-13 0 11 2024-06-19
21115 ¼­¿ï 2024 Àç°ü·ùÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2024-07-13 0 10 2024-06-19
21114 ¼­¿ï Çѱ¹¹é³»Àå±¼Àý¼ö¼úÇÐȸ 2024 KSCRS Annual Symposium(1ÀÏÂ÷) : 2024-07-13 0 8 2024-06-19
21113 ¼­¿ï 2024 ´ç´¢º´½ÅÁõ ½ÉÆ÷Áö¾ö : 2024-07-13 0 8 2024-06-19
21112 ¼­¿ï ´ëÇÑÇ÷°üÇÐȸ KOVAS 2024 Summer Conference (1ÀÏÂ÷) : 2024-07-12 0 10 2024-06-19
21111 ¼­¿ï 2024 ´ëÇѽÅÃéÀåÀ̽Ŀܰú¿¬±¸È¸ ÇÏ°è Çмú´ëȸ : 2024-07-12 0 8 2024-06-19
21110 ¼­¿ï ´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Çϰ迬¼ö±³À° : 2024-07-12 0 11 2024-06-19
21109 ¼­¿ï (¿Â¶óÀÎ) ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ – Á¦5Â÷ Àå¾ÖÆÇÁ¤ ¿Â¶óÀÎ ½ÉÆ÷Áö¾ö : 2024-07-07 0 12 2024-06-19
21108 ¼­¿ï 2024³â ´ëÇѺñ´¢ºÎÀΰúÇÐȸ Á¦27Â÷ Çмú´ëȸ (¿ÀÇÁ¶óÀÎ) : 2024-07-07 0 7 2024-06-19
21107 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2024 ºñ´¢»ý½Ä¿µ»óÀÇÇÐ ¿¬¼ö°­Á : 2024-07-07 0 12 2024-06-19
21106 ¼­¿ï 2024³â Çϰ迬¼ö°­Á ¹× Á¦1ȸ ¿¹¹æÁ¢Á¾ ½ÉÆ÷Áö¾ö : 2024-07-07 0 14 2024-06-19
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷